Trials / Completed
CompletedNCT05967156
Empagliflozin in Heart Failure Dialysis Patients
Safety and Efficacy of Empagliflozin on Heart Failure Dialysis Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Shahid Beheshti University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Empagliflozin is not still approved for glomerular filtration rate \< 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.
Detailed description
Heart failure dialysis patients with residual renal function will be followed up on Empagliflozin based on echocardiographic parameters, pro-brain natriuretic peptide levels, diuresis volume, and serum acidity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin10Mg Tab | 10 mg daily |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2025-06-01
- Completion
- 2025-06-03
- First posted
- 2023-08-01
- Last updated
- 2025-06-06
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT05967156. Inclusion in this directory is not an endorsement.